Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
47
GYRE Quote, Financials, Valuation and Earnings
Last price:
$6.81
Seasonality move
:
12.42%
Day range:
$6.90 - $7.06
52-week range:
$6.11 - $13.75
Dividend yield:
0%
P/E ratio:
179.21x
P/S ratio:
6.26x
P/B ratio:
6.44x
Volume:
61.3K
Avg. volume:
77.7K
1-year change:
-41.65%
Market cap:
$656M
Revenue:
$105.8M
EPS (TTM):
$0.04
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GYRE
Gyre Therapeutics, Inc.
|
$36.3M | -- | 30.25% | -100% | $18.00 |
|
ADMA
ADMA Biologics, Inc.
|
$139.9M | $0.20 | 18.97% | -56.04% | $25.67 |
|
EXEL
Exelixis, Inc.
|
$609.2M | $0.76 | 7.5% | 59.24% | $45.28 |
|
MRKR
Marker Therapeutics, Inc.
|
$682K | -$0.19 | -69.71% | -54.94% | $7.33 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -13.45% | $10.81 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$59.3M | -- | 11.45% | -- | $13.13 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GYRE
Gyre Therapeutics, Inc.
|
$6.81 | $18.00 | $656M | 179.21x | $0.00 | 0% | 6.26x |
|
ADMA
ADMA Biologics, Inc.
|
$17.89 | $25.67 | $4.3B | 21.00x | $0.00 | 0% | 9.00x |
|
EXEL
Exelixis, Inc.
|
$43.58 | $45.28 | $11.7B | 18.35x | $0.00 | 0% | 5.45x |
|
MRKR
Marker Therapeutics, Inc.
|
$1.54 | $7.33 | $25.7M | -- | $0.00 | 0% | 4.18x |
|
SVRA
Savara, Inc.
|
$5.64 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$8.25 | $13.13 | $487.5M | -- | $0.00 | 0% | 2.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GYRE
Gyre Therapeutics, Inc.
|
1.13% | 0.706 | 0.16% | 5.45x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -3.305 | 2.38% | 3.53x |
|
EXEL
Exelixis, Inc.
|
7.55% | 0.175 | 1.59% | 3.47x |
|
MRKR
Marker Therapeutics, Inc.
|
-- | 1.778 | -- | 5.66x |
|
SVRA
Savara, Inc.
|
24.02% | -2.174 | 4.83% | 7.42x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | -0.960 | 3.7% | 2.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GYRE
Gyre Therapeutics, Inc.
|
$28.9M | $6.9M | 10.26% | 10.4% | 22.66% | $4.3M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
EXEL
Exelixis, Inc.
|
$579.2M | $256.4M | 28.73% | 31.26% | 42.89% | $288.8M |
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$2.1M | -103.04% | -103.04% | -173.31% | -$2.7M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
Gyre Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns GYRE or ADMA?
ADMA Biologics, Inc. has a net margin of 19.42% compared to Gyre Therapeutics, Inc.'s net margin of 27.14%. Gyre Therapeutics, Inc.'s return on equity of 10.4% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital GYREGyre Therapeutics, Inc.94.67% $0.03 $138.6M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About GYRE or ADMA?
Gyre Therapeutics, Inc. has a consensus price target of $18.00, signalling upside risk potential of 164.32%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 40.72%. Given that Gyre Therapeutics, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Gyre Therapeutics, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GYREGyre Therapeutics, Inc.2 0 0 ADMAADMA Biologics, Inc.3 0 0 -
Is GYRE or ADMA More Risky?
Gyre Therapeutics, Inc. has a beta of 2.906, which suggesting that the stock is 190.583% more volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.466, suggesting its less volatile than the S&P 500 by 53.393%.
-
Which is a Better Dividend Stock GYRE or ADMA?
Gyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gyre Therapeutics, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GYRE or ADMA?
Gyre Therapeutics, Inc. quarterly revenues are $30.6M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Gyre Therapeutics, Inc.'s net income of $5.9M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Gyre Therapeutics, Inc.'s price-to-earnings ratio is 179.21x while ADMA Biologics, Inc.'s PE ratio is 21.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gyre Therapeutics, Inc. is 6.26x versus 9.00x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GYREGyre Therapeutics, Inc.6.26x 179.21x $30.6M $5.9M ADMAADMA Biologics, Inc.9.00x 21.00x $134.2M $36.4M
-
Which has Higher Returns GYRE or EXEL?
Exelixis, Inc. has a net margin of 19.42% compared to Gyre Therapeutics, Inc.'s net margin of 32.38%. Gyre Therapeutics, Inc.'s return on equity of 10.4% beat Exelixis, Inc.'s return on equity of 31.26%.
Company Gross Margin Earnings Per Share Invested Capital GYREGyre Therapeutics, Inc.94.67% $0.03 $138.6M EXELExelixis, Inc.96.89% $0.70 $2.3B -
What do Analysts Say About GYRE or EXEL?
Gyre Therapeutics, Inc. has a consensus price target of $18.00, signalling upside risk potential of 164.32%. On the other hand Exelixis, Inc. has an analysts' consensus of $45.28 which suggests that it could grow by 3.9%. Given that Gyre Therapeutics, Inc. has higher upside potential than Exelixis, Inc., analysts believe Gyre Therapeutics, Inc. is more attractive than Exelixis, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GYREGyre Therapeutics, Inc.2 0 0 EXELExelixis, Inc.9 9 0 -
Is GYRE or EXEL More Risky?
Gyre Therapeutics, Inc. has a beta of 2.906, which suggesting that the stock is 190.583% more volatile than S&P 500. In comparison Exelixis, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.171%.
-
Which is a Better Dividend Stock GYRE or EXEL?
Gyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gyre Therapeutics, Inc. pays -- of its earnings as a dividend. Exelixis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GYRE or EXEL?
Gyre Therapeutics, Inc. quarterly revenues are $30.6M, which are smaller than Exelixis, Inc. quarterly revenues of $597.8M. Gyre Therapeutics, Inc.'s net income of $5.9M is lower than Exelixis, Inc.'s net income of $193.6M. Notably, Gyre Therapeutics, Inc.'s price-to-earnings ratio is 179.21x while Exelixis, Inc.'s PE ratio is 18.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gyre Therapeutics, Inc. is 6.26x versus 5.45x for Exelixis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GYREGyre Therapeutics, Inc.6.26x 179.21x $30.6M $5.9M EXELExelixis, Inc.5.45x 18.35x $597.8M $193.6M
-
Which has Higher Returns GYRE or MRKR?
Marker Therapeutics, Inc. has a net margin of 19.42% compared to Gyre Therapeutics, Inc.'s net margin of -162.11%. Gyre Therapeutics, Inc.'s return on equity of 10.4% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.
Company Gross Margin Earnings Per Share Invested Capital GYREGyre Therapeutics, Inc.94.67% $0.03 $138.6M MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M -
What do Analysts Say About GYRE or MRKR?
Gyre Therapeutics, Inc. has a consensus price target of $18.00, signalling upside risk potential of 164.32%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.33 which suggests that it could grow by 376.19%. Given that Marker Therapeutics, Inc. has higher upside potential than Gyre Therapeutics, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Gyre Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GYREGyre Therapeutics, Inc.2 0 0 MRKRMarker Therapeutics, Inc.3 0 0 -
Is GYRE or MRKR More Risky?
Gyre Therapeutics, Inc. has a beta of 2.906, which suggesting that the stock is 190.583% more volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.371, suggesting its more volatile than the S&P 500 by 37.092%.
-
Which is a Better Dividend Stock GYRE or MRKR?
Gyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gyre Therapeutics, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GYRE or MRKR?
Gyre Therapeutics, Inc. quarterly revenues are $30.6M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.2M. Gyre Therapeutics, Inc.'s net income of $5.9M is higher than Marker Therapeutics, Inc.'s net income of -$2M. Notably, Gyre Therapeutics, Inc.'s price-to-earnings ratio is 179.21x while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gyre Therapeutics, Inc. is 6.26x versus 4.18x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GYREGyre Therapeutics, Inc.6.26x 179.21x $30.6M $5.9M MRKRMarker Therapeutics, Inc.4.18x -- $1.2M -$2M
-
Which has Higher Returns GYRE or SVRA?
Savara, Inc. has a net margin of 19.42% compared to Gyre Therapeutics, Inc.'s net margin of --. Gyre Therapeutics, Inc.'s return on equity of 10.4% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital GYREGyre Therapeutics, Inc.94.67% $0.03 $138.6M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About GYRE or SVRA?
Gyre Therapeutics, Inc. has a consensus price target of $18.00, signalling upside risk potential of 164.32%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 91.71%. Given that Gyre Therapeutics, Inc. has higher upside potential than Savara, Inc., analysts believe Gyre Therapeutics, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GYREGyre Therapeutics, Inc.2 0 0 SVRASavara, Inc.6 0 0 -
Is GYRE or SVRA More Risky?
Gyre Therapeutics, Inc. has a beta of 2.906, which suggesting that the stock is 190.583% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.278, suggesting its less volatile than the S&P 500 by 72.168%.
-
Which is a Better Dividend Stock GYRE or SVRA?
Gyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gyre Therapeutics, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GYRE or SVRA?
Gyre Therapeutics, Inc. quarterly revenues are $30.6M, which are larger than Savara, Inc. quarterly revenues of --. Gyre Therapeutics, Inc.'s net income of $5.9M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Gyre Therapeutics, Inc.'s price-to-earnings ratio is 179.21x while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gyre Therapeutics, Inc. is 6.26x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GYREGyre Therapeutics, Inc.6.26x 179.21x $30.6M $5.9M SVRASavara, Inc.-- -- -- -$29.6M
-
Which has Higher Returns GYRE or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of 19.42% compared to Gyre Therapeutics, Inc.'s net margin of -40.15%. Gyre Therapeutics, Inc.'s return on equity of 10.4% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital GYREGyre Therapeutics, Inc.94.67% $0.03 $138.6M VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About GYRE or VNDA?
Gyre Therapeutics, Inc. has a consensus price target of $18.00, signalling upside risk potential of 164.32%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.13 which suggests that it could grow by 59.09%. Given that Gyre Therapeutics, Inc. has higher upside potential than Vanda Pharmaceuticals, Inc., analysts believe Gyre Therapeutics, Inc. is more attractive than Vanda Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GYREGyre Therapeutics, Inc.2 0 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is GYRE or VNDA More Risky?
Gyre Therapeutics, Inc. has a beta of 2.906, which suggesting that the stock is 190.583% more volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.647%.
-
Which is a Better Dividend Stock GYRE or VNDA?
Gyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gyre Therapeutics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GYRE or VNDA?
Gyre Therapeutics, Inc. quarterly revenues are $30.6M, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Gyre Therapeutics, Inc.'s net income of $5.9M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Gyre Therapeutics, Inc.'s price-to-earnings ratio is 179.21x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gyre Therapeutics, Inc. is 6.26x versus 2.28x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GYREGyre Therapeutics, Inc.6.26x 179.21x $30.6M $5.9M VNDAVanda Pharmaceuticals, Inc.2.28x -- $56.3M -$22.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 2
Claritev Corp. [CTEV] is down 20.7% over the past day.
Sell
47
ASTS alert for Jan 2
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
Buy
60
BIDU alert for Jan 3
Baidu, Inc. [BIDU] is up 15.01% over the past day.
